MX2021008263A - Métodos de tratamiento de afecciones relacionadas con el receptor s1p1. - Google Patents

Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.

Info

Publication number
MX2021008263A
MX2021008263A MX2021008263A MX2021008263A MX2021008263A MX 2021008263 A MX2021008263 A MX 2021008263A MX 2021008263 A MX2021008263 A MX 2021008263A MX 2021008263 A MX2021008263 A MX 2021008263A MX 2021008263 A MX2021008263 A MX 2021008263A
Authority
MX
Mexico
Prior art keywords
sub
methods
receptor
conditions related
treating conditions
Prior art date
Application number
MX2021008263A
Other languages
English (en)
Inventor
Snehal Naik
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MX2021008263A publication Critical patent/MX2021008263A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Se proporcionan métodos para seleccionar individuos para el tratamiento con ácido (R)-2-(7-(4- ciclopentil-3-(trifluorometil)b enciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3-il)acético (Compuesto 1) o una sal, hidrato o solvato farmacéuticamente aceptable de este.
MX2021008263A 2019-01-08 2020-01-08 Métodos de tratamiento de afecciones relacionadas con el receptor s1p1. MX2021008263A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962789937P 2019-01-08 2019-01-08
PCT/US2020/012783 WO2020146529A1 (en) 2019-01-08 2020-01-08 Methods of treating conditions related to the s1p1 receptor

Publications (1)

Publication Number Publication Date
MX2021008263A true MX2021008263A (es) 2021-10-13

Family

ID=69467760

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008263A MX2021008263A (es) 2019-01-08 2020-01-08 Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.

Country Status (10)

Country Link
US (1) US20220142977A1 (es)
EP (1) EP3908276A1 (es)
JP (1) JP2022516662A (es)
KR (1) KR20210113298A (es)
CN (1) CN113874009A (es)
AU (1) AU2020206700A1 (es)
CA (1) CA3124701A1 (es)
IL (1) IL284114A (es)
MX (1) MX2021008263A (es)
WO (1) WO2020146529A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
MX2017008925A (es) 2015-01-06 2017-10-11 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
HUE060476T2 (hu) 2015-06-22 2023-03-28 Arena Pharm Inc (R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
US11478448B2 (en) 2017-02-16 2022-10-25 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
JP7265620B2 (ja) * 2018-10-03 2023-04-26 アリーナ ファーマシューティカルズ， インコーポレイテッド 強皮症の治療のための方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104311472B9 (zh) 2008-07-23 2020-03-17 艾尼纳制药公司 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
MX2017008925A (es) * 2015-01-06 2017-10-11 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.

Also Published As

Publication number Publication date
WO2020146529A1 (en) 2020-07-16
AU2020206700A1 (en) 2021-07-15
EP3908276A1 (en) 2021-11-17
IL284114A (en) 2021-08-31
US20220142977A1 (en) 2022-05-12
JP2022516662A (ja) 2022-03-01
CA3124701A1 (en) 2020-07-16
KR20210113298A (ko) 2021-09-15
CN113874009A (zh) 2021-12-31

Similar Documents

Publication Publication Date Title
MX2021008263A (es) Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.
MX2020013157A (es) Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.
CR20220258A (es) Inhibidores de kras g12c
MX2021000310A (es) Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidin-2,6-diona y su uso en el tratamiento de las enfermedades que dependen de la familia de dedo de zinc ikaros (ikzf2).
CR20210001A (es) Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteina con dedos de zinc 2 de la familia ikaros (1kzf2)
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2020002060A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos.
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
CR20210501A (es) Inhibidores de la proteína tirosina fosfatasa
MX2021001690A (es) Indoles sustituidos y metodos de uso de los mismos.
TN2018000130A1 (en) N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
WO2010088050A3 (en) Bicyclic pyrazolo-heterocycles
EP3310760B8 (en) Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in s1p1 receptor-associated disorders
WO2008130879A3 (en) Tetrahydroindole and tetrahydroindazole derivatives
WO2008157751A3 (en) Substituted imidazoheterocycles
TW200613306A (en) Imidazotriazines as protein kinase inhibitors
MX2021011606A (es) Compuestos dirigidos a prmt5.
EP3957631A4 (en) QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR THE TREATMENT OF EWING'S SARCOMA
MX2021013531A (es) Inhibidores de cdk.
MX2022008342A (es) Metodos para tratar afecciones relacionadas con el receptor de s1p1.
ATE399156T1 (de) Neue indol- oder benzimidazol-derivate
EA200870454A1 (ru) Способ ингибирования c-kit киназы
MX2020008746A (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado.
JP2017525717A5 (es)
MX2022006083A (es) Metodos para tratar afecciones relacionadas con el receptor s1p1.